The assumption
Made to order means the product has been checked for me by the FDA.
What the answer rests on
A medicine prepared to order by a doctor or pharmacist is called compounded. FDA stands for Food and Drug Administration, the federal agency that oversees drugs. As of September 2026, it does not approve compounded drugs or review their safety, results, or quality before marketing.
The reason for making changes
A patient need can explain the choice
FDA stands for Food and Drug Administration, the federal agency that oversees drugs. It says compounding may be appropriate when an approved drug cannot meet a patient’s medical need or is not commercially available.
As of September 2026, federal limits restrict repeated copying of available medicines and copies made in large amounts. For an individual patient, the person writing the prescription can decide that a change meets a medical need the ready-made drug does not.
This is called a significant difference: a change that matters for that patient’s medical need. As of September 2026, a lower price alone does not qualify.
The short version
Ask what the change is doing
| Ask the person writing the prescription | Ask the pharmacy |
|---|---|
| What need can the ready-made medicine not meet? | What exact ingredients are in this preparation? |
| What change matters for me? | Who makes it, and which rules cover that work? |
| How is that decision recorded? | What written product information comes with it? |
Two layers of compounding rules
A shortage and a local stock problem differ
As of September 2026, when a drug is on FDA’s national shortage list, the usual federal limits on making copies do not apply. A drug does not join that national list just because a local pharmacy has none in stock.
As of September 2026, FDA’s shortage list contains neither tirzepatide injections nor semaglutide injections. The temporary periods allowing broad copying because of those shortages have also ended. An offer of a made-to-order version now needs its own explanation under the remaining rules.
As of September 2026, Illinois adds two conditions for making a version of a ready-made drug. The ready-made product must be unavailable through normal medicine suppliers in time to meet the patient’s needs. The person writing the prescription must also request the made-to-order version. Both the Illinois conditions and the federal limits must be met; a local stock problem alone does not remove those federal limits.
As of September 2026, FDA says adding a vitamin does not automatically stop a similar semaglutide product from counting as a copy.
Ask for the patient-specific reason in plain words. An answer about the exact need is more useful than a claim that all compounding is allowed or all compounding is forbidden.
Ask why this prescription differs
What change meets my medical need, and what rules cover this medicine?
Keep a question in your notesEvidence for this chapter
Chapter notes
- FDA: compounding questions
Patient needs, oversight, and the absence of product approval.
- FDA: copy and shortage policies
The agency’s updates on semaglutide and tirzepatide.
- Illinois: the compounding definition
The state conditions for ready-made products.